Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.39%167.01B | 5.70%152.68B | 2.01%41.06B | 11.47%41.57B | 17.84%39.86B | -8.72%30.18B | 6.61%144.44B | 2.56%40.26B | 2.07%37.29B | 11.57%33.83B |
| Cost of revenue | 7.57%149.01B | 7.14%138.53B | 3.07%36.74B | 13.42%38.02B | 18.20%35.93B | -6.38%27.84B | 5.95%129.3B | 1.71%35.64B | 1.52%33.52B | 12.68%30.4B |
| Gross profit | 27.15%17.99B | -6.54%14.15B | -6.14%4.33B | -5.92%3.55B | 14.60%3.93B | -29.60%2.34B | 12.61%15.14B | 9.56%4.61B | 7.19%3.77B | 2.60%3.43B |
| Operating expense | 10.23%11.12B | 6.82%10.09B | 18.57%2.89B | 3.93%2.51B | 0.62%2.27B | 3.55%2.42B | 9.73%9.45B | 11.40%2.43B | 9.21%2.42B | 10.39%2.25B |
| Selling and administrative expenses | 10.23%11.12B | 6.82%10.09B | ---- | ---- | ---- | ---- | 9.73%9.45B | ---- | ---- | ---- |
| -Selling and marketing expense | --0 | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| -General and administrative expense | 10.23%11.12B | 6.82%10.09B | ---- | ---- | ---- | ---- | 9.75%9.45B | ---- | ---- | ---- |
| Operating profit | 69.25%6.87B | -28.71%4.06B | -33.79%1.44B | -23.54%1.03B | 41.31%1.67B | -108.21%-81M | 17.72%5.69B | 7.57%2.18B | 3.76%1.35B | -9.59%1.18B |
| Net non-operating interest income (expenses) | -47.17%-78M | 33.75%-53M | -58.82%-27M | 68.18%-7M | 66.67%-7M | 40.00%-12M | 1.23%-80M | 22.73%-17M | -15.79%-22M | -5.00%-21M |
| Non-operating interest income | 46.15%114M | 212.00%78M | 133.33%21M | 420.00%26M | 200.00%18M | 160.00%13M | 8.70%25M | 80.00%9M | -16.67%5M | 0.00%6M |
| Non-operating interest expense | 46.56%192M | 24.76%131M | 84.62%48M | 22.22%33M | -7.41%25M | 0.00%25M | 0.96%105M | -3.70%26M | 8.00%27M | 3.85%27M |
| Net investment income | -48.88%160M | 24.70%313M | 202.94%103M | 42.28%-86M | -32.33%90M | -11.59%206M | 13.06%251M | -64.21%34M | -312.86%-149M | 565.00%133M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 646.67%82M | 42.31%-15M | -50.00%-15M | 0 | 0 | 0 | -104.81%-26M | -101.85%-10M | 0 | -1M |
| Income from associates and other participating interests | 0.00%3M | 0.00%3M | -50.00%1M | 1M | 0.00%1M | 0 | 200.00%3M | 100.00%2M | 0 | 1M |
| Special income (charges) | -112.50%-329M | 328.83%2.63B | 1,966.21%2.71B | -53M | -104.61%-35M | 15M | 4,193.33%614M | -145M | 0 | 25,400.00%759M |
| Less:Other special charges | 100.04%1M | -269.83%-2.81B | ---2.8B | --0 | --3M | ---15M | -5,160.00%-759M | --0 | --0 | ---- |
| Less:Write off | 88.51%328M | 20.00%174M | -38.62%89M | --53M | ---- | ---- | --145M | --145M | --0 | ---- |
| Other non-operating income (expenses) | -454.05%-262M | 39.62%74M | 3,275.00%135M | 2M | -225.58%-54M | -250.00%-9M | 171.62%53M | 500.00%4M | 0 | 166.15%43M |
| Income before tax | -8.13%6.44B | 7.79%7.01B | 112.89%4.34B | -24.79%889M | -20.63%1.66B | -90.08%118M | 19.78%6.51B | -22.64%2.04B | -10.93%1.18B | 69.14%2.09B |
| Income tax | -16.72%1.67B | -4.53%2B | 74.19%1.18B | -12.93%303M | -23.68%519M | -99.75%1M | 26.45%2.1B | -4.91%678M | -22.84%348M | 66.67%680M |
| Net income | -4.67%4.77B | 13.64%5.01B | 132.16%3.16B | -29.74%586M | -19.22%1.14B | -85.41%116M | 16.87%4.41B | -29.21%1.36B | -4.79%834M | 70.48%1.42B |
| Net income continuous operations | -4.69%4.77B | 13.66%5.01B | 132.16%3.16B | -29.74%586M | -19.17%1.14B | -85.30%117M | 16.84%4.41B | -29.21%1.36B | -4.79%834M | 70.36%1.41B |
| Noncontrolling interests | -75.89%81M | 63.11%336M | 176.67%83M | -6.86%95M | 89.74%74M | 140.00%84M | 880.95%206M | 1,400.00%30M | 1,600.00%102M | 457.14%39M |
| Net income attributable to the company | 0.47%4.69B | 11.19%4.67B | 130.98%3.08B | -33.06%490M | -22.25%1.07B | -95.79%32M | 12.06%4.2B | -30.61%1.33B | -15.96%732M | 67.07%1.38B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 0.47%4.69B | 11.19%4.67B | 130.98%3.08B | -33.06%490M | -22.25%1.07B | -95.79%32M | 12.06%4.2B | -30.61%1.33B | -15.96%732M | 67.07%1.38B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 0.43%58.21 | 11.25%57.96 | 131.08%38.206 | -32.86%6.094 | -22.23%13.258 | -95.74%0.402 | 12.11%52.098 | -30.54%16.534 | -15.92%9.076 | 67.07%17.048 |
| Diluted earnings per share | 0.43%58.21 | 11.25%57.96 | 130.83%38.1608 | -32.92%6.088 | -22.23%13.258 | -95.74%0.402 | 12.11%52.098 | -30.55%16.5322 | -15.92%9.076 | 67.07%17.048 |
| Dividend per share | 0.99%41 | 6.28%40.6 | 6.28%40.6 | 0 | 0 | 0 | 5.23%38.2 | 5.23%38.2 | 0 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |